Marc  Schegerin net worth and biography

Marc Schegerin Biography and Net Worth

CFO of Morphic
Presently, Marc Schegerin occupies the position of Chief Operating & Financial Officer of Morphic Holding, Inc. and Chief Financial & Operating Officer at Morphic Therapeutic, Inc. (a subsidiary of Morphic Holding, Inc.). Dr. Schegerin is also on the board of SQZ Biotechnologies Co.

In the past Marc Schegerin was Treasurer, Chief Financial Officer & Head-Strategy at ArQule, Inc.

Dr. Schegerin received a doctorate from Dartmouth Medical School, an MBA from Tuck School of Business at Dartmouth and an undergraduate degree from Tulane University (Louisiana).

What is Marc Schegerin's net worth?

The estimated net worth of Marc Schegerin is at least $2.16 million as of July 8th, 2024. Dr. Schegerin owns 37,907 shares of Morphic stock worth more than $2,160,320 as of November 21st. This net worth estimate does not reflect any other investments that Dr. Schegerin may own. Additionally, Dr. Schegerin receives an annual salary of $722,380.00 as CFO at Morphic. Learn More about Marc Schegerin's net worth.

How old is Marc Schegerin?

Dr. Schegerin is currently 48 years old. There are 6 older executives and no younger executives at Morphic. The oldest executive at Morphic is Dr. Timothy A. Springer Ph.D., Founder, Independent Director & Member of Scientific Advisory Board, who is 76 years old. Learn More on Marc Schegerin's age.

What is Marc Schegerin's salary?

As the CFO of Morphic Holding, Inc., Dr. Schegerin earns $722,380.00 per year. There are 2 executives that earn more than Dr. Schegerin. The highest earning executive at Morphic is Dr. Praveen P. Tipirneni M.D., CEO, MD & Director, who commands a salary of $991,330.00 per year. Learn More on Marc Schegerin's salary.

How do I contact Marc Schegerin?

The corporate mailing address for Dr. Schegerin and other Morphic executives is 35 Gatehouse Drive A2, Waltham MA, 02451. Morphic can also be reached via phone at (781) 996-0955. Learn More on Marc Schegerin's contact information.

Has Marc Schegerin been buying or selling shares of Morphic?

Marc Schegerin has not been actively trading shares of Morphic over the course of the past ninety days. Most recently, Marc Schegerin sold 43,936 shares of the business's stock in a transaction on Monday, July 8th. The shares were sold at an average price of $55.80, for a transaction totalling $2,451,628.80. Following the completion of the sale, the chief financial officer now directly owns 37,907 shares of the company's stock, valued at $2,115,210.60. Learn More on Marc Schegerin's trading history.

Who are Morphic's active insiders?

Morphic's insider roster includes Robert Farrell, Jr. (CAO), Peter Linde (Insider), Bruce Rogers (Insider), Marc Schegerin (CFO), and Timothy Springer (Director). Learn More on Morphic's active insiders.

Are insiders buying or selling shares of Morphic?

During the last twelve months, insiders at the sold shares 10 times. They sold a total of 161,666 shares worth more than $8,004,797.42. The most recent insider tranaction occured on July, 8th when President Bruce Rogers sold 20,000 shares worth more than $1,115,800.00. Insiders at Morphic own 25.6% of the company. Learn More about insider trades at Morphic.

Information on this page was last updated on 7/8/2024.

Marc Schegerin Insider Trading History at Morphic

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/8/2024Sell43,936$55.80$2,451,628.8037,907View SEC Filing Icon  
1/16/2024Sell6,041$27.49$166,067.0937,460View SEC Filing Icon  
9/7/2023Sell20,000$54.34$1,086,800.0024,136View SEC Filing Icon  
4/25/2023Sell50,000$54.71$2,735,500.0024,136View SEC Filing Icon  
3/7/2023Sell50,000$45.00$2,250,000.0017,074View SEC Filing Icon  
1/14/2023Sell1,670$30.63$51,152.1016,212View SEC Filing Icon  
11/1/2021Sell5,477$60.00$328,620.00View SEC Filing Icon  
10/26/2021Sell37$60.00$2,220.00View SEC Filing Icon  
10/14/2021Sell24,184$60.02$1,451,523.68View SEC Filing Icon  
See Full Table

Marc Schegerin Buying and Selling Activity at Morphic

This chart shows Marc Schegerin's buying and selling at Morphic by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Morphic Company Overview

Morphic logo
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $56.99
Low: $56.99
High: $56.99

50 Day Range

MA: $56.76
Low: $55.74
High: $56.99

2 Week Range

Now: $56.99
Low: $19.34
High: $57.00

Volume

400 shs

Average Volume

1,272,131 shs

Market Capitalization

$2.85 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.49